Venture Capital

Inipharm Raises $35M In Series A To Focus On Highly Validated Genetic Target Hsd17b13

by vcaonline.com posted 2weeks ago 25 views
-Initial therapeutic pipeline to target liver diseases -5AM Ventures and Wu Capital join existing investors Frazier Healthcare Partners and Jubilant Biosys Limited SEATTLE & SAN DIEGO, November 11, 2020-- Inipharm today announced the close of a $35 million Series A financing round. Founded in 2018, the company is focused on discovering and developing therapies for liver and related diseases, with its initial program focused on those associated with the genetically defined target HSD17B13. The Series A funding will support the advancement of Inipharm’s lead program through IND filing and into clinical trials.

In this article